Monday , February 18 2019
Home / Delaware Marijuana News / Columbia Care Introduces Nation’s First High-CBD Extended Release Tablets

Columbia Care Introduces Nation’s First High-CBD Extended Release Tablets


Columbia Care, one of the nation’s leading medical marijuana companies, has introduced a high-CBD formulation of its full spectrum medical marijuana tablets. Following last month’s debut of the high-THC tablet formulation, this novel product marks the next step forward in innovation and management of chronic illness.

“The success Columbia Care is achieving in product innovation allows us to provide the most comprehensive, cutting-edge care options for medical marijuana patients,” said Columbia Care CEO Nicholas Vita.  “As more patients are discovering the benefits of this medicine, we are continuing to meet their needs with expanded treatment options and novel products. At Columbia Care, we take the medicinal breadth of the hundreds of active compounds in the cannabis plant and bring scientific rigor and medical expertise to maximize the benefits of this medicine. By combining some of nature’s most powerful compounds with cutting-edge science and manufacturing capabilities, we are improving treatment options and realizing our missing of giving patients the better quality of life they deserve.”

Columbia Care’s patent-pending tablets are designed using proprietary, precisely manufactured formulations that include a targeted portfolio of the most important active compounds that are deliberately concentrated, while preserving the broad chemical profile of selected cultivars.  These tablets are pre-scored for ‘splitting’ to create additional titration and dosing options. Furthermore, all tablets are imprinted with the Columbia Care logo and product identification to provide additional product safety confirmation for the patient.

The tablets will be available to patients and their caregivers at Columbia Care’s New York dispensaries, or online through Columbia Care’s home delivery option. By years end, Columbia Care plans to make this product available, along with its other pharmaceutical quality products, through its national organization including, but not limited to, FloridaOhioDelawarePennsylvaniaMassachusettsIllinoisArizonaPuerto RicoCalifornia and Washington, D.C.